Patent ID: 9140687
Filing Date: 2015-09-22
Classification: A61P,C12Q,G01N

Abstract:
1. A method of diagnosing renal cancer, comprising: obtaining a biological sample from a subject with renal cancer or suspected of having renal cancer; contacting a sample obtained from the subject with renal cancer or suspected of having renal cancer with at least two antibodies capable of detecting at least two of cadherin-5 precursor, cadherin-11 precursor, pyruvate kinase isozymes M1/M2, and probable ATP-dependent RNA helicase (DDX23); measuring protein expression of at least two of cadherin-5 precursor, cadherin-11 precursor, pyruvate kinase isozymes M1/M2, and probable ATP-dependent RNA helicase (DDX23) in a biological sample obtained from a subject with renal cancer or suspected of having renal cancer by performing Western Blot analysis or an enzyme-linked immunosorbent assay (ELISA) that detects at least two of cadherin-5 precursor, cadherin-11 precursor, pyruvate kinase isozymes M1/M2, and probable ATP-dependent RNA helicase (DDX23); and determining the presence of renal cancer in the subject by comparing protein expression level of at least two or more of proteins cadherin-5 precursor, cadherin-11 precursor, pyruvate kinase isozymes M1/M2, and probable ATP-dependent RNA helicase (DDX23) in the sample obtained from the subject with renal cancer or suspected of having renal cancer with the protein expression level of the at least two or more proteins expressed in a non-tumor sample wherein an at least 2-fold increase in protein expression level of at least two or more of these proteins relative to protein expression level in the non-tumor sample indicates that the subject has renal cancer.